|
Acute leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This is the first report of the transposition of MOS in association with acute leukemia.
|
2522812 |
1989 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
|
2567285 |
1989 |
|
Adenocarcinoma of lung (disorder)
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Adrenal Gland Pheochromocytoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.
|
8695346 |
1996 |
|
Adult Non-Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly these fragile sites were located in the same chromosomal bands as the oncogenes, MOS, MYC, BCL-1 and BCL-2 as well as cancer breakpoints specifically associated with non-Hodgkin's lymphoma, suggesting the possibility that fragile sites may play a critical role in the pathogenesis of non-Hodgkin's lymphoma.
|
7954347 |
1994 |
|
Adult Non-Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
|
2567285 |
1989 |
|
Arthritis, Psoriatic
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition to clinical characteristics including presence of exposed lesions, data were collected using the Psoriatic Arthritis (PsA) Screening and Evaluation (PASE), Dermatology Life Quality Index (DLQI), MOS 36-Item Short-Form Health Survey (SF-36), Work Productivity and Activity Impairment Questionnaire Psoriasis (WPAI: PSO) and Medication Satisfaction Questionnaire (MSQ).
|
29430733 |
2018 |
|
Asthenia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We observed a significant improvement in visual analogic scales at six month for dysmenorrhea (-3.6, p=0.004), dyspareunia (-2.4, p=0.006), diarrhea (-3.0, p=0.006), constipation (-3, p=0.002), dyschezia (-3.2, p=0.003), false urges to defecate (-3.3, p=0.007), posterior pelvic pain (-3.8, p=0.002), and asthenia (-4.3, p=0.002).There was also a significant improvement of the MOS-SF36 with an increase of both Physical Composite Score (+9.3%, p=0.002) and Mental Composite Score (+10.9%, p=0.017) at six months.
|
31788875 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
We have, therefore, analyzed the level of transcription of the cellular myc and mos genes in a variety of undifferentiated B cell lymphomas of Burkitt and non-Burkitt type that possess either an 8;14 or an 8;22 translocation.
|
6300881 |
1983 |
|
Back Pain
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
They used a self-administered the Roland Morris Disability Questionnaire (RDQ), the Japanese Orthopaedic Association Back Pain Questionnaire (JOABPEQ), MOS 36-Item Short-Form Health Survey (SF-36), and satisfaction for surgery (VAS) were completed.
|
31806423 |
2019 |
|
Bodily Pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Convergent validity was demonstrated with PAL-I total score and Roland-Morris Disability Questionnaire (Pearson correlation 0.82), MOS-36 Physical Functioning (-0.71), and MOS-36 Bodily Pain (-0.71).
|
29889120 |
2018 |
|
Bodily Pain
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The MOS 36-item Short-Form Health Survey was completed at baseline and 6, 12, and 24 months after surgery; the bodily pain, physical functioning, and role-physical subscales were used for this analysis (higher scores = less disability).
|
31201809 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In the case of Ha-MSV-containing constructs stably integrated in the two human breast cancer lines, however, CAT expression was more than two orders of magnitude greater than that transiently expressed in these cells.
|
2825673 |
1987 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
The 5-kb allele of the MOS oncogene, previously proposed to be associated with breast cancer, was absent in these families, suggesting that polymorphism at this locus is not associated with inherited susceptibility.
|
2564734 |
1989 |
|
Cancer Pain
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Pain and Medical Outcomes Study Sleep questionnaire (MOS-Sleep) were assessed at baseline and 3 months after opioid titration in 231 opioid naïve CNCP patients.
|
30700073 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Alterations of K-ras and c-mos, two pivotal components of this pathway, have been implicated in non-small cell lung carcinogenesis.
|
11778648 |
2001 |
|
Carcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
These findings suggest that c-mos and L-myc RFLPs might be helpful in identifying those individuals who are at a higher risk of developing laryngeal carcinomas.
|
1679639 |
1991 |
|
Carcinoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The carcinomas with concomitant alterations of c-mos and p53 [c-mos(P)/p53 positive] had significantly lower AI values (P < 0.001) and were more frequently associated with aneuploidy (P = 0.015) than the c-mos(N)/p53 negative tumors but not the c-mos(N)/p53 positive tumors, which suggests that p53 status is the main determinant of ploidy status and apoptosis in our series.
|
11212247 |
2001 |
|
Carcinoma of bladder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we report preliminary results indicating that the T24 bladder carcinoma oncogene is highly related to the transforming gene of BALB-MSV, an acute transforming retrovirus.
|
6761348 |
1982 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Alterations of chromosomes (3p, 5q, 9p), genes (Rb, C-myc, C-mos, hTERT), proteins (p16, p53, K-ras, hnRNP A2/B1, MCM2, EGFR, erbB-2, erbB-3, erbB-4) and others can be found in lung cancer.
|
15452456 |
2004 |
|
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We generated three human c-mos-specific antisera and report here the detection of c-mos protein in a human neuroblastoma cell line, SK-N-BE2 (BE2).
|
8502488 |
1993 |
|
Cerebrovascular accident
|
0.010 |
Biomarker
|
group |
BEFREE |
The current study examines how stroke severity (NIH Stroke Scale), its impact on perceived mobility (Stroke Impact Scale mobility domain), and the environment (MOS Social Support-Positive Social Interactions scale and Measure of Stroke Environment receptivity and built environment domains) influence social participation (Activity Card Sort: ACS).
|
30800187 |
2019 |
|
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We generated three human c-mos-specific antisera and report here the detection of c-mos protein in a human neuroblastoma cell line, SK-N-BE2 (BE2).
|
8502488 |
1993 |
|
Childhood Non-Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The EcoRI RFLP of c-mos in patients with non-Hodgkin's lymphoma and acute lymphoblastic leukemia, compared to geriatric and non-geriatric controls.
|
2567285 |
1989 |
|
Childhood Non-Hodgkin Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interestingly these fragile sites were located in the same chromosomal bands as the oncogenes, MOS, MYC, BCL-1 and BCL-2 as well as cancer breakpoints specifically associated with non-Hodgkin's lymphoma, suggesting the possibility that fragile sites may play a critical role in the pathogenesis of non-Hodgkin's lymphoma.
|
7954347 |
1994 |